neoadjuvant immunotherapy
Phase 2Small molecule
neoadjuvant immunotherapy is one of 93 small molecule programs targeting Delirium. It is currently in Phase 2.
4
Indications
6
Total Trials
4
Active Trials
92
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
PORTRAZZA
Eli LillyPreclinical
neoadjuvant immunotherapy
RRenJi Hospital
Phase 2
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Delirium1 trial
Gastric Cancer1 trial
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07050524·80 enrolled
1 more indication
Neoadjuvant Immunotherapy1 trial
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Recruiting·—··NCT06317558·4,000 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for neoadjuvant immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRenJi Hospital